SCHEMBL3528939

SCHEMBL3528939

O=C(O)Cc1nc2ncccn2n1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.44
NPC1 O15118 2/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
ALDH1A1 P00352 2/20 0.43
KDM4E B2RXH2 2/20 0.43
TSHR P16473 1/20 0.43
APOBEC3A P31941 1/20 0.41
APOBEC3G Q9HC16 1/20 0.41
USP2 O75604 1/20 0.40
LMNA P02545 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
THRB P10828 1/20 0.37
PDE10A Q9Y233 2/20 0.37
HPGD P15428 3/20 0.36
MAPT P10636 2/20 0.36
CYP1A2 P05177 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9933875 0.80 RAB9A (0.45) RAB9ANPC1MEN1KMT2AALDH1A1
SCHEMBL4473144 0.80 NPC1 (0.45) RAB9ANPC1MEN1KMT2AALDH1A1
SCHEMBL13954223 0.76 NPC1 (0.45) RAB9ANPC1MEN1KMT2AALDH1A1
SCHEMBL4158096 0.75 MEN1 (0.57) RAB9ANPC1MEN1KMT2AALDH1A1
SCHEMBL9941419 0.72 JAK2 (0.45) PDE10AMAPT
SCHEMBL874090 0.70 CYP1A2 (0.50) ALDH1A1KDM4ETSHRLMNAMAPT
SCHEMBL9101730 0.70 ALDH1A1 (0.55) RAB9ANPC1MEN1KMT2AALDH1A1
SCHEMBL17324580 0.70 ALDH1A1 (0.55) RAB9ANPC1MEN1KMT2AALDH1A1
SCHEMBL7195074 0.70 PDE10A (0.45) RAB9ANPC1MEN1KMT2AALDH1A1
Hydrochloric Acid SCHEMBL6645397 0.68 KDM4E (0.48) ALDH1A1KDM4ETSHRLMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7645771-B2 CCR5 antagonists as therapeutic agents SMITHKLINE BEECHAM CORP. (US) 2010-01-12 US disclosed
US-20060229336-A1 Ccr5 antagonists as therapeutic agents SMITHKLINE BEECHAM CORPORATION 2006-10-12 US disclosed
EP-1569646-A2 PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2005-09-07 EP disclosed
WO-2004054974-A2 PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2004-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060229336-A1 Ccr5 antagonists as therapeutic agents CCR5, CCR1, CXCR3 RAB9A 2633/4885NPC1 279/4885MEN1 4561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.